We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

ELITechGroup

Offers a range of products for in vitro diagnostics in clinical chemistry, hemostasis, microbiology, immunology, and ... read more Featured Products: More products

Download Mobile App




Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus

By LabMedica International staff writers
Posted on 29 Dec 2023

Bruker Corporation (Billerica, MA, USA), an international life science research and diagnostics solutions provider, has entered into separate agreements to acquire ELITechGroup (Puteaux, France), a global manufacturer of in-vitro diagnostics (IVD), and Phasefocus Holdings Limited (Sheffield, UK), a cell imaging company. More...

The acquisitions are expected to strengthen Bruker’s position in molecular diagnostics and microscopy, respectively.

According to a Dec. 26 regulatory filing, Bruker will acquire ELITech for a purchase price derived from an enterprise value of USD 966.1 million, subject to certain adjustments. ELITech has been owned and operated by private equity firm PAI Partners (Paris, France) since 2017. ELITech specializes in developing and manufacturing IVD instruments and reagents and enjoys a strong market position in niche IVD segments in molecular diagnostics and microbiology. The company offers products to hospitals and laboratories for diagnosing diseases, identifying disease risk factors, and optimizing treatment choices. ELITech has undertaken transformative initiatives, such as R&D investments, the launch of next-generation molecular diagnostics systems, and new strategic partnerships for product development. These initiatives have strengthened ELITech’s competitive position and improved its reputation as an industry innovator, resulting in significant financial growth and profitability.

“Our partnership with PAI, together with the hard work and drive for innovation of our teams, have helped develop ELITech into the company that it is today,” said Christoph Gauer, CEO of ELITech Group. “It’s incredibly rewarding to see that our collective efforts have been a success and position us well for this exciting next chapter. I’d like to thank PAI for their support over the years and look forward to what the ELITech team can achieve as part of Bruker.”

In a separate transaction, Bruker has signed a definitive agreement to acquire Phasefocus, a privately held company with leading expertise in imaging and image processing algorithms. Financial details of the transaction were not disclosed. Phasefocus has developed a novel optical microscope, called Livecyte, for label-free imaging that is based on strong algorithms and patented technology. Phasefocus’ microscopy capabilities will enhance Bruker’s existing portfolio, enabling new research advances in a range of cell imaging applications while Bruker’s global reach will help build on Phasefocus’ success to date.

“Phasefocus has extensive image processing and algorithm expertise that they have nicely deployed in their Livecyte product,” said Dr. Frank Burgaezy, President AXS division. “This is a good addition to our broad imaging portfolio and their technology will enable us to drive further product developments.”

“We are very pleased to join Bruker,” added Dr. Martin Humphry, CEO of Phasefocus. “Joining forces with a leading life-science tools provider with broad geographic reach enables us to give many more researchers access to our products for investigation of dynamic single cell behavior.”

Related Links:

Bruker Corporation
ELITechGroup
PAI Partners
Phasefocus Holdings Limited 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Staining System
RAL DIFF-QUIK
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Brain biomarkers of Alzheimer\'s disease can be detected as early as middle age (Photo courtesy of University of Shutterstock)

Blood-Based Biomarkers Could Detect Alzheimer's as Early as Middle Age

As the global population ages, Alzheimer's disease and other dementing diseases are becoming more prevalent. The disease processes leading to Alzheimer's symptoms can begin years or even decades before... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.